MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

We analysed the prognostic significance of minimal residual disease (MRD) level in adult patients with acute myeloid leukemia (AML) treated in the randomized gemtuzumab ozogamicin (GO) ALFA-0701 trial. Levels of WT1 and NPM1 gene transcripts were assessed using cDNA-based real-time quantitative PCR...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Lambert, Juliette, Lambert, Jérôme, Nibourel, Olivier, Pautas, Cécile, Hayette, Sandrine, Cayuela, Jean-Michel, Terré, Christine, Rousselot, Philippe, Dombret, Hervé, Chevret, Sylvie, Preudhomme, Claude, Castaigne, Sylvie, Renneville, Aline
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2014
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171629/
https://ncbi.nlm.nih.gov/pubmed/25026287
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia